Sanofi - Aug 2, 2021 Form 4 Insider Report for Icosavax, Inc. (ICVX)

Role
10%+ Owner
Signature
/s/ Alexander Roger, Head of Securities Law and Capital Markets
Stock symbol
ICVX
Transactions as of
Aug 2, 2021
Transactions value $
$1,000,005
Form type
4
Date filed
8/2/2021, 08:34 PM
Previous filing
Jul 28, 2021
Next filing
Sep 14, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICVX Common Stock (par value, $0.0001) Conversion of derivative security $0 +3.09M $0.00 3.09M Aug 2, 2021 Through its wholly-owned subsidiary, Aventis Inc. F1, F2
transaction ICVX Common Stock (par value, $0.0001) Purchase $1M +66.7K +2.16% $15.00 3.16M Aug 2, 2021 Through its wholly-owned subsidiary, Aventis Inc. F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICVX Series A-1 Preferred Stock (par value, $0.0001) Conversion of derivative security -12.5M -100% 0 Aug 2, 2021 Common Stock 3M $0.00 Through its wholly-owned subsidiary, Aventis Inc F1, F2
transaction ICVX Series B-1 Preferred Stock (par value, $0.0001) Conversion of derivative security -354K -100% 0 Aug 2, 2021 Common Stock 85.3K $0.00 Through its wholly-owned subsidiary, Aventis Inc F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sanofi is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's Common Stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer.
F2 Sanofi is the beneficial owner of 3,155,169 Shares of Common Stock of the Issuer through its wholly owned subsidiary, Aventis, Inc.
F3 The reporting person acquired additional shares in the Issuer's initial public offering.